515 related articles for article (PubMed ID: 33666253)
61. Broad-Spectrum Antiviral Activity of 3D8, a Nucleic Acid-Hydrolyzing Single-Chain Variable Fragment (scFv), Targeting SARS-CoV-2 and Multiple Coronaviruses In Vitro.
Lee G; Budhathoki S; Lee GY; Oh KJ; Ham YK; Kim YJ; Lim YR; Hoang PT; Lee Y; Lim SW; Kim JM; Cho S; Kim TH; Song JW; Lee S; Kim WK
Viruses; 2021 Apr; 13(4):. PubMed ID: 33918914
[TBL] [Abstract][Full Text] [Related]
62. Mechanism of SARS-CoV-2 polymerase stalling by remdesivir.
Kokic G; Hillen HS; Tegunov D; Dienemann C; Seitz F; Schmitzova J; Farnung L; Siewert A; Höbartner C; Cramer P
Nat Commun; 2021 Jan; 12(1):279. PubMed ID: 33436624
[TBL] [Abstract][Full Text] [Related]
63. A review on the interaction of nucleoside analogues with SARS-CoV-2 RNA dependent RNA polymerase.
Khan S; Attar F; Bloukh SH; Sharifi M; Nabi F; Bai Q; Khan RH; Falahati M
Int J Biol Macromol; 2021 Jun; 181():605-611. PubMed ID: 33766591
[TBL] [Abstract][Full Text] [Related]
64. Combination Treatment With Remdesivir and Ivermectin Exerts Highly Synergistic and Potent Antiviral Activity Against Murine Coronavirus Infection.
Tan YL; Tan KSW; Chu JJH; Chow VT
Front Cell Infect Microbiol; 2021; 11():700502. PubMed ID: 34395311
[TBL] [Abstract][Full Text] [Related]
65. Antiviral activity of digoxin and ouabain against SARS-CoV-2 infection and its implication for COVID-19.
Cho J; Lee YJ; Kim JH; Kim SI; Kim SS; Choi BS; Choi JH
Sci Rep; 2020 Oct; 10(1):16200. PubMed ID: 33004837
[TBL] [Abstract][Full Text] [Related]
66. Remdesivir: A beacon of hope from Ebola virus disease to COVID-19.
Nili A; Farbod A; Neishabouri A; Mozafarihashjin M; Tavakolpour S; Mahmoudi H
Rev Med Virol; 2020 Nov; 30(6):1-13. PubMed ID: 33210457
[TBL] [Abstract][Full Text] [Related]
67. Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system.
Yuan S; Chan JFW; Chik KKH; Chan CCY; Tsang JOL; Liang R; Cao J; Tang K; Chen LL; Wen K; Cai JP; Ye ZW; Lu G; Chu H; Jin DY; Yuen KY
Pharmacol Res; 2020 Sep; 159():104960. PubMed ID: 32473310
[TBL] [Abstract][Full Text] [Related]
68. Understanding the binding mechanism for potential inhibition of SARS-CoV-2 Mpro and exploring the modes of ACE2 inhibition by hydroxychloroquine.
Choudhury M; Dhanabalan AK; Goswami N
J Cell Biochem; 2022 Feb; 123(2):347-358. PubMed ID: 34741481
[TBL] [Abstract][Full Text] [Related]
69. A bacterial artificial chromosome (BAC)-vectored noninfectious replicon of SARS-CoV-2.
Zhang Y; Song W; Chen S; Yuan Z; Yi Z
Antiviral Res; 2021 Jan; 185():104974. PubMed ID: 33217430
[TBL] [Abstract][Full Text] [Related]
70. A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agents.
Do TND; Donckers K; Vangeel L; Chatterjee AK; Gallay PA; Bobardt MD; Bilello JP; Cihlar T; De Jonghe S; Neyts J; Jochmans D
Antiviral Res; 2021 Aug; 192():105122. PubMed ID: 34186107
[TBL] [Abstract][Full Text] [Related]
71. Screening of FDA-Approved Drugs Using a MERS-CoV Clinical Isolate from South Korea Identifies Potential Therapeutic Options for COVID-19.
Ko M; Chang SY; Byun SY; Ianevski A; Choi I; Pham Hung d'Alexandry d'Orengiani AL; Ravlo E; Wang W; Bjørås M; Kainov DE; Shum D; Min JY; Windisch MP
Viruses; 2021 Apr; 13(4):. PubMed ID: 33918958
[TBL] [Abstract][Full Text] [Related]
72. RNA-dependent RNA polymerase: Structure, mechanism, and drug discovery for COVID-19.
Jiang Y; Yin W; Xu HE
Biochem Biophys Res Commun; 2021 Jan; 538():47-53. PubMed ID: 32943188
[TBL] [Abstract][Full Text] [Related]
73. Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp3 papain-like protease.
Lim CT; Tan KW; Wu M; Ulferts R; Armstrong LA; Ozono E; Drury LS; Milligan JC; Zeisner TU; Zeng J; Weissmann F; Canal B; Bineva-Todd G; Howell M; O'Reilly N; Beale R; Kulathu Y; Labib K; Diffley JFX
Biochem J; 2021 Jul; 478(13):2517-2531. PubMed ID: 34198325
[TBL] [Abstract][Full Text] [Related]
74. Development of alveolar and airway cells from human iPS cells: toward SARS-CoV-2 research and drug toxicity testing.
Tsuji K; Yamada S; Hirai K; Asakura H; Kanda Y
J Toxicol Sci; 2021; 46(9):425-435. PubMed ID: 34470994
[TBL] [Abstract][Full Text] [Related]
75. Remdesivir for the treatment of Covid-19: the value of biochemical studies.
Götte M
Curr Opin Virol; 2021 Aug; 49():81-85. PubMed ID: 34052732
[TBL] [Abstract][Full Text] [Related]
76. CETSA MS Profiling for a Comparative Assessment of FDA-Approved Antivirals Repurposed for COVID-19 Therapy Identifies TRIP13 as a Remdesivir Off-Target.
Friman T; Chernobrovkin A; Martinez Molina D; Arnold L
SLAS Discov; 2021 Mar; 26(3):336-344. PubMed ID: 33208020
[TBL] [Abstract][Full Text] [Related]
77. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus.
Gordon CJ; Tchesnokov EP; Feng JY; Porter DP; Götte M
J Biol Chem; 2020 Apr; 295(15):4773-4779. PubMed ID: 32094225
[TBL] [Abstract][Full Text] [Related]
78. The
Hu Y; Meng X; Zhang F; Xiang Y; Wang J
Emerg Microbes Infect; 2021 Dec; 10(1):317-330. PubMed ID: 33560940
[TBL] [Abstract][Full Text] [Related]
79. Uncertainty about the Efficacy of Remdesivir on COVID-19.
Yoo JH
J Korean Med Sci; 2020 Jun; 35(23):e221. PubMed ID: 32537956
[No Abstract] [Full Text] [Related]
80. Characterization and Treatment of SARS-CoV-2 in Nasal and Bronchial Human Airway Epithelia.
Pizzorno A; Padey B; Julien T; Trouillet-Assant S; Traversier A; Errazuriz-Cerda E; Fouret J; Dubois J; Gaymard A; Lescure FX; Dulière V; Brun P; Constant S; Poissy J; Lina B; Yazdanpanah Y; Terrier O; Rosa-Calatrava M
Cell Rep Med; 2020 Jul; 1(4):100059. PubMed ID: 32835306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
